PharmaEssentia: Net income surged 106% year-over-year on strong sales, with major investments in cell therapy and manufacturing
Займёт меньше минуты
Revenue and net income more than doubled year-over-year for the nine months ended September 30, 2025, driven by robust medicine sales and global expansion. The company faces ongoing arbitration risks but maintains strong liquidity and is investing in cell therapy and manufacturing capacity.
Original document: PharmaEssentia Corp. [6446] Interim report — Dec. 1 2025
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr